Objective To investigate the clinical efficacy and safety of tacrolimus combined with glucocorticoid therapy in treating steroid-resistant nephrotic syndrome. Methods 20 patients with steroid-resistant nephrotic syndrome were enrolled and received com-bination therapy of tacrolimus and glucocorticoid. The indicators were tested before treatment and 1, 3, 6 months later. Main outcome measure:the 24 h urinary protein excretion, plasma albumin ( Alb ) blood urea nitrogen ( BUN ) , serum creatinine ( Scr ) , total cholesterol ( TC ) , triglyceride ( TG ) , Alanine transaminase ( ALT ) , Aspartate Aminotransferase ( AST ) , blood sugar. The treatment efficacy is evaluated and the occurrence of adverse reactions was recorded. Results Compared with pre-therapy, after 1, 3, 6 months' treatment, the 24 h urinary protein excretion was reduced and the Alb was increased significantly ( P < 0. 05 ); after 3, 6 months' treatment, the TC and TG de-creased significantly ( P < 0. 05 ) . The ALT, AST, BUN, Scr, blood sugar didn't change obviously between before and after the treatment. At the end of 3, 6 months, the total effective rate was 95. 00%;at the end of 6 month, the total cure rate was 25. 00%. Adverse reactions were all mild, and the patient can be tolerated. Conclusion Tacrolimus combined with glucocorticoid has a good efficacy in treating steroid-resistant nephrotic syndrome with no severe adverse reactions occurred.%目的：探讨他克莫司联合激素治疗激素抵抗型肾病综合征（SRNS）的临床疗效。方法选取医院接受治疗的激素抵抗型肾病综合征患者20例，采用他克莫司联合激素治疗，观察治疗前、治疗后1，3，6个月患者的各项临床指标变化，并记录不良反应发生情况。结果与治疗前比较，治疗后1，3，6个月24 h尿蛋白定量明显降低，血白蛋白明显升高，3，6个月总胆固醇、三酰甘油明显降低，差异有统计学差异（ P<0.05）；肝肾功能、血糖水平未发生明显改变，均在正常范围内；治疗后3个月和6个月总有效率达95.00%，治疗6个月总治愈率达25.00%；不良反应均较轻微，患者可以耐受。结论他克莫司联合激素治疗SRNS可在短期内获得较好疗效，同时不良反应较轻。
展开▼
